新型卡博拉尼尔-BODIPY合物:设计,合成和抗癌活性
Chandra Sekhara Mahanta1, Sunitee Hansdah2, Kabita Khuntia2
1Department of Chemistry Ravenshaw University College Square Cuttack 753003 Odisha India rashmi.satapathy@gmail.com.
RSC advances
|October 31, 2024
概括
新的carboranyl-BODIPY化合物显示出作为抗癌剂的前景. 联合的o-CB-10显示出显著的癌细胞死亡,并抑制了HeLa细胞的增殖和迁移.
科学领域:
- 有机化学 有机化学
- 药用化学 医学化学
- 癌症研究 癌症研究
背景情况:
- 集群和BODIPY光体是开发新型治疗剂的关键组成部分.
- 卡博拉尼尔-BODIPY结合物将团的独特特性与BODIPY的光物理特性相结合.
研究的目的:
- 合成和描述新型的卡博拉尼尔-BODIPY和烯-BODIPY合物.
- 评估这些合成化合物的体外细胞毒性和抗癌潜力,与HeLa宫癌细胞系对比.
主要方法:
- 合成卡博拉尼尔-BODIPY和烯-BODIPY联合体.
- 使用NMR (1H, 13C, 11B, 19F),FT-IR和高分辨率质谱法进行表征.
- 在体外细胞毒性测定和HeLa细胞的流细胞计分析.
主要成果:
- 合成的合物,包括o-CB-10,m-CB-15,Me-o-CB-28,Me-o-CB-35和PB-20,已经成功地准备和表征.
- 在低度 (12.03μM) 的情况下,o-CB-10对HeLa细胞表现出显著的细胞毒性,抑制细胞增殖和迁移.
- 发现o-CB-10和Me-o-CB-28可以在S阶段阻止细胞循环.
结论:
- 卡博拉尼尔-BODIPY结合物显示出作为有效的抗癌剂的潜力.
- 化合物o-CB-10由于其强大的细胞毒性作用和抑制癌细胞生长和运动的能力,特别有前途.
- 对这些卡博拉尼尔-BODIPY合物进行进一步的研究是有必要的,以便它们作为治疗药物的发展.
相关概念视频
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165


